TCR-CD3 bispecific antibodies(T-Therapeutics Inc)

N/A

Report date: 2026/03/19 16:34:38

First In Class

Base Information

Drug NameTCR-CD3 bispecific antibodies(T-Therapeutics Inc)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionAnti-CD3Anti-T-cell receptor

TargetsT cell surface glycoprotein CD3T-cell receptor

Therapy Area/IndicationsSolid tumoursAutoimmune Diseases

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited Kingdom

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesT-Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesT-Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsSolid tumoursAutoimmune Diseases

Inactive IndicationsN/A

Other Information

ATC CodeN/A